Starting July 1, 2026, people responding to severe allergic reactions may give epinephrine through FDA-approved nasal sprays and other methods.
The law allows epinephrine for severe allergic reactions to be given through nasal sprays and other FDA-approved methods, as well as injectable devices.
The law allows epinephrine to be given through FDA-approved delivery methods. This covers epinephrine used to treat anaphylaxis, a severe allergic reaction, including emergencies involving students and other people. The method must be approved by the U.S. Food and Drug Administration. A person giving epinephrine under the general emergency provision must act in good faith. The main provisions take effect July 1, 2026. The rulemaking section takes effect as soon as the steps for the act to become law are complete.
No hearings or votes scheduled.